12:00 AM
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tarceva erlotinib regulatory update

Astellas submitted an sNDA to FDA to expand the label of Tarceva erlotinib to include first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations as detected by an approved test. Astellas said...

Read the full 193 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >